Daniel Legén

ENERGOCHEMICA SE operates as a holding company, which engages in the chemical and energy industry. Its products include facade profile systems, windows and doors profiles, polymers, PVC products, aldehyde materials, and light stabilizers. The firm operates through the following segments: Chemistry, Power, Biotechnology, Construction, and Automotive Industry. The Chemistry segment supplies raw materials and semi-finished polymers, chlorine, and cladding materials. The Power segment supplies energy to internal and external customers. The Biotechnology segment engages in the refinery of biomass. The Construction segment manufactures hydraulic mixtures, cement, concrete additives, facade, window and door profiles, as well as semi-finished plastic goods for the production of furniture. The Automotive Industry segment supplies finished plastic components, and chemicals used during automobile assembly. The company was founded on December 15, 2011 and is headquartered in Prague, Czech Republic.

Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot clinical stage biotech company that specializes in peptide-based vaccines for treating fatal human diseases. The company is based in Larnaca, Cyprus. AXON Neuroscience has the single biggest team in the world dedicated exclusively to tau research in relation to treating Alzheimer's disease, with over 60 scientists and 15 senior scientific leaders. The company's lead vaccine, AADvac1, is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's disease. AXON Neuroscience has extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology, which allowed it to move quickly in creating its novel peptide vaccine against COVID-19. The company was founded in 1999 by Michal Novak. Michal Fresser has been the CEO of the company since 2013.